The primary molecular targets were clinically relevant gene fusions in NSCLC, including ALK, ROS1, RET, and NTRK1/2/3, as well as MET and FGFR3, which are not currently part of the recommended national testing panel, as studies in the scientific literature have reported their potential association with NSCLC and therapeutic relevance [4,13,14]. The gene discussed is MET; the disease is non-small cell lung carcinoma.